ライフサイエンスコーパス: renal cell

1 s one of the top ATG-interacting proteins in renal cells.

2 iting AMP-activated protein kinase (AMPK) in renal cells.

3 nal tissue for evidence of SARS-CoV-2 within renal cells.

4 intrinsic kidney injury produced by damaged renal cells and by neutrophils.

5 ntial regulation of Cyp27b1 in renal and non-renal cells and has implications for vitamin D biology i

6 ic key downstream events of BMP signaling in renal cells and have yielded a lead BMP agonist.

7 This review will focus on the role of S1P in renal cells and how aberrant extracellular and intracell

8 9 is a more potent inhibitor of apoptosis in renal cells and induced less decreases in intracellular

9 Single-cell analysis of intrinsic renal cells and infiltrating cells from patients with LN

10 Furthermore, AREG's effects on renal cells and monocytes/macrophages (M/M) were analyze

11 ly and reproducibly using mixed immortalized renal cells, and showed their application for renal toxi

12 e (PT-DsbA-L-KO) attenuated UUO-induced TIF, renal cell apoptosis and inflammation.

13 ial cell AGEs and RAGE levels, pulmonary and renal cell apoptosis, and the progression of chronic ren

14 anscription factors and tumor suppressors in renal cell cancer (RCC).

15 uamous cell cancers, 2 with melanoma, 1 with renal cell cancer, and 1 with adenocarcinoma of the lung

16 oval for the treatment of advanced melanoma, renal cell cancer, and non-small cell lung cancer.

17 nts with a prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent whole-body PET/

18 ifferent tumours, such as breast, ovarian or renal cell cancer.

19 th melanoma, non-small-cell lung cancer, and renal cell cancer.

20 All renal cell cancers and most breast cancers, non-Hodgkin

21 All 12 renal cell cancers showed a low binding of sst2 with the

22 umab + axitinib versus sunitinib in advanced renal cell carcinoma (aRCC).

23 Clear cell renal cell carcinoma (CC-RCC) is the most lethal of all

24 lly quiet kidney tumor, clear cell papillary renal cell carcinoma (CCPAP).

25 care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiog

26 in mouse models of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal cancer.

27 ckpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and other solid tumors.

28 In this study, we focused on clear cell renal cell carcinoma (ccRCC) and utilized RNA sequencing

29 tomic and epigenomic profiling of clear cell renal cell carcinoma (ccRCC) by The Cancer Genome Atlas

30 mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The Cancer Genom

31 The adipocyte-like morphology of clear cell renal cell carcinoma (ccRCC) cells results from a grade-

32 The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investigated exten

33 Clear cell renal cell carcinoma (ccRCC) has been previously classif

34 Although clear cell renal cell carcinoma (ccRCC) has been shown to result in

35 n of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through

36 on Hippel-Lindau (VHL)-associated clear cell renal cell carcinoma (ccRCC) has the potential to allow

37 ecent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered novel driver

38 he molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and progression

39 Clear-cell renal cell carcinoma (ccRCC) is a common aggressive urin

40 Clear cell renal cell carcinoma (ccRCC) is a gender-biased tumor.

41 Clear cell renal cell carcinoma (CCRCC) is an incurable malignancy

42 Clear cell renal cell carcinoma (ccRCC) is highly heterogeneous and

43 Clear cell renal cell carcinoma (ccRCC) is histologically defined b

44 Clear cell renal cell carcinoma (ccRCC) is the most common renal ca

45 Clear cell renal cell carcinoma (ccRCC) is the most common type of

46 aled to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also ver

47 This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although key mutatio

48 In clear cell renal cell carcinoma (ccRCC), AXL expression is associat

49 formed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resist

50 The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by geneti

51 been termed a tumor-suppressor in clear cell renal cell carcinoma (ccRCC), primarily based on functio

52 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamin

53 the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common form of ki

54 Clear-cell renal cell carcinoma (ccRCC), the most common subtype of

55 ted functional modules that drive clear cell renal cell carcinoma (ccRCC), we performed comprehensive

56 ressor and is highly expressed in clear cell renal cell carcinoma (ccRCC), where SLC2A3 expression is

57 pha) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC).

58 y, regulates lipid homeostasis in clear cell renal cell carcinoma (ccRCC).

59 BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

60 protein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

61 iR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).

62 used by VHL inactivation, such as clear-cell renal cell carcinoma (ccRCC).

63 le in improving the management of clear cell renal cell carcinoma (ccRCC).

64 as indicative of poor survival in clear cell renal cell carcinoma (ccRCC).

65 dulating metastasis of VHL-mutant clear cell renal cell carcinoma (ccRCC).

66 pes from The Cancer Genome Atlas: clear cell renal cell carcinoma (ccRCC, also known as kidney renal

67 Chromophobe renal cell carcinoma (chRCC) accounts for approximately

68 Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are cl

69 Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is characterized by germlin

70 ancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a disease in which mutatio

71 ach to analyze hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a type of kidney cancer th

72 rafenib efficacy in patients with metastatic renal cell carcinoma (mRCC) are not available.

73 ict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lacking.

74 is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires

75 TOR (mTORi) approved for treating metastatic renal cell carcinoma (mRCC).

76 us a tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC).

77 2%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]).

78 tigate ITH and clonal evolution of papillary renal cell carcinoma (pRCC) and rarer kidney cancer subt

79 Papillary renal cell carcinoma (PRCC) is the most common type of R

80 cipients, for example, have a 7-fold risk of renal cell carcinoma (RCC) and 3-fold risk of urothelial

81 during tumour initiation and progression in renal cell carcinoma (RCC) and three oncometabolites - f

82 ined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnorma

83 h an increased risk of developing clear cell renal cell carcinoma (RCC) but, paradoxically, obesity i

84 activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro.

85 we identify PAX8 as a candidate oncogene in Renal Cell Carcinoma (RCC) cells.

86 Renal cell carcinoma (RCC) comprises a diverse group of

87 e somatic genetic and genomic alterations in renal cell carcinoma (RCC) encompassing the major RCC hi

88 sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate o

89 For the past decade, advanced renal cell carcinoma (RCC) has been at the forefront of

90 The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized over

91 tment landscape for patients with metastatic renal cell carcinoma (RCC) has evolved dramatically.

92 The management pathways of advanced renal cell carcinoma (RCC) have considerably evolved in

93 ssification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the rec

94 Renal cell carcinoma (RCC) incidence is increasing world

95 Renal cell carcinoma (RCC) is a cancer with poor prognos

96 Cystic renal cell carcinoma (RCC) is almost certainly overdiagn

97 Renal cell carcinoma (RCC) is one of the most aggressive

98 Renal cell carcinoma (RCC) is one of the most lethal uro

99 Renal cell carcinoma (RCC) is polyresistant to chemo- an

100 ism underlying GM2-synthase de-repression in renal cell carcinoma (RCC) is poorly understood.

101 These findings show that angiogenesis in renal cell carcinoma (RCC) is regulated through AXL/S100

102 Renal cell carcinoma (RCC) is the most common type of ki

103 omics evaluation of 823 tumors from advanced renal cell carcinoma (RCC) patients identifies molecular

104 romo-1 (PBRM1) on TME and response to ICB in renal cell carcinoma (RCC) remains to be resolved.

105 Background Percutaneous ablation for cT1 renal cell carcinoma (RCC) remains underused, partially

106 Renal cell carcinoma (RCC) subtypes are characterized by

107 D), and otherwise PN; biopsy, with triage of renal cell carcinoma (RCC) to PN or ablation depending o

108 peutic response and resistance in metastatic renal cell carcinoma (RCC) treated with antiangiogenic t

109 Human renal cell carcinoma (RCC) tumors were stained for the N

110 etabolism, contributes to the progression of renal cell carcinoma (RCC) via a novel epitranscriptomic

111 the outcomes of microwave ablation (MWA) of renal cell carcinoma (RCC) with and without pyeloperfusi

112 d with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any

113 increasingly utilized treatment for stage I renal cell carcinoma (RCC), albeit without supportive le

114 of gastrointestinal stromal tumors (GISTs), renal cell carcinoma (RCC), and pancreatic cancer, has b

115 ty-related factors have been associated with renal cell carcinoma (RCC), but it is unclear which indi

116 In renal cell carcinoma (RCC), cells deficient in the von H

117 Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous

118 have been associated with increased risk of renal cell carcinoma (RCC), the most common form of kidn

119 s regions, obtained from three patients with renal cell carcinoma (RCC), were imaged.

120 amined the tumorogenic role of syntaxin 6 in renal cell carcinoma (RCC).

121 t cancer types but have yet to be studied in renal cell carcinoma (RCC).

122 ies (GWAS) have identified six risk loci for renal cell carcinoma (RCC).

123 l heterogeneity in MB, malignant glioma, and renal cell carcinoma (RCC).

124 alue of MPV in the prognostic evaluations of renal cell carcinoma (RCC).

125 and breast, but its role remains unclear in renal cell carcinoma (RCC).

126 therapy given as a first-line treatment for renal cell carcinoma (RCC).

127 lid tumors was followed by dose expansion in renal cell carcinoma (RCC).

128 itical role in the growth and progression of renal cell carcinoma (RCC).

129 receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC).

130 ntrol mechanisms are only poorly analyzed in renal cell carcinoma (RCC).

131 nical trial of the combination in metastatic renal cell carcinoma (RCC).

132 ear cell carcinoma (KIRC) is the most common renal cell carcinoma (RCC).

133 rs (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC).

134 cer epithelial cells, the cells of origin of renal cell carcinoma (RCC).

135 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15).

136 h A498 primary site and ACHN metastatic site renal cell carcinoma (RRC) cell lines.

137 TFE3 Xp11.2 translocation renal cell carcinoma (TFE3-RCC) generally progresses mor

138 melanoma and a mouse model of translocation renal cell carcinoma (tRCC).

139 sorafenib vs placebo in resected unfavorable renal cell carcinoma [RCC]), the largest adjuvant trial

140 r prediction of local tumor recurrence after renal cell carcinoma ablation.

141 patients with previously untreated advanced renal cell carcinoma across all risk categories.

142 n of local tumor recurrence in patients with renal cell carcinoma after thermal ablation.

143 Pre-treatment determination of renal cell carcinoma aggressiveness may help guide clini

144 viously published datasets of 100 clear-cell renal cell carcinoma and 99 non-small-cell lung cancer p

145 ically or cytologically confirmed metastatic renal cell carcinoma and at least two previous systemic

146 to uveal melanoma, mesothelioma, meningioma, renal cell carcinoma and basal cell carcinoma.

147 some 8q24.1 (encompassing MYC) in clear cell renal cell carcinoma and chromosome 11q13.3 (encompassin

148 ed by RECIST 1.1 in patients with clear cell renal cell carcinoma and how the progression events impa

149 rtunity for previously treated patients with renal cell carcinoma and non-small-cell carcinoma.

150 versus sunitinib in patients with metastatic renal cell carcinoma and showed a favourable safety prof

151 ses have identified subtypes of conventional renal cell carcinoma broadly distributed into angiogenic

152 eptor and a shift in the current standard of renal cell carcinoma care.

153 Intriguingly, clear cell renal cell carcinoma cells (ccRCC) have a dysregulated l

154 27 induced apoptosis and cell death in 786-O renal cell carcinoma cells (EC(50) = 5 muM) and inhibite

155 However, clinically significant capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due

156 te or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria.

157 were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk category a

158 d was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and

159 were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status int

160 didate identified was the hepatocellular and renal cell carcinoma drug sorafenib.

161 characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles

162 had been functionally disabled in the human renal cell carcinoma environment without unleashing unde

163 neous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma had similar excellent intermediate-

164 Treatment for renal cell carcinoma has been revolutionised by inhibito

165 Renal cell carcinoma has long been understood to have a

166 resent the case of endovascular treatment of renal cell carcinoma in patient with solitary kidney.

167 tween 1998 and 2010 for localised clear cell renal cell carcinoma in the USA).

168 suppress ccRCC progression.The incidence of renal cell carcinoma is higher in males than in females

169 Identification of high-risk localised renal cell carcinoma is key for the selection of patient

170 cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised.

171 482 pathologically confirmed renal cell carcinoma lesions from 2008 to 2019 in a mult

172 many advances in the treatment of metastatic renal cell carcinoma of the clear cell type.

173 nib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in cle

174 Methods: In a relevant renal cell carcinoma patient-derived xenograft model, we

175 e serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an

176 ibly increased complications following CN in renal cell carcinoma patients, when TKI treatment is adm

177 the postoperative morbidity following CN in renal cell carcinoma patients.

178 g staging system for prediction of localised renal cell carcinoma recurrence after surgery, which mig

179 SNPs) to improve the predictive accuracy for renal cell carcinoma recurrence and investigated whether

180 er Genome Atlas breast cancer and clear cell renal cell carcinoma studies.

181 ive ongoing studies targeting non-clear-cell renal cell carcinoma subtypes and specific molecular alt

182 s applied to a chicken embryo tumor model of renal cell carcinoma that was treated with two FDA-appro

183 dominant ganglioside isolated from malignant renal cell carcinoma tissues, is reported.

184 Guangdong, China) with localised clear cell renal cell carcinoma to examine 44 potential recurrence-

185 112 identified patients with non-clear-cell renal cell carcinoma treated at the participating centre

186 y of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib duri

187 71.9 years +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with thermal ablatio

188 t non-invasively predicting Fuhrman grade of renal cell carcinoma using conventional MRI.

189 hrman I-II) from high-grade (Fuhrman III-IV) renal cell carcinoma using radiomics features extracted

190 common causes for radiologic progression of renal cell carcinoma were based on non-target disease an

191 ment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 201

192 Glioma and renal cell carcinoma were prioritized because these tumo

193 of (99m)Tc-PHC-102 in SPECT in patients with renal cell carcinoma while also assessing the safety and

194 versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand

195 with histologically confirmed non-clear-cell renal cell carcinoma who received cabozantinib for metas

196 We identified 627 patients with Stage IV renal cell carcinoma who underwent CN from 2007-2010 uti

197 itrated axitinib in patients with metastatic renal cell carcinoma who were previously treated with ch

198 previously untreated, advanced or metastatic renal cell carcinoma with a clear-cell component were re

199 nced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were re

200 18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enro

201 ly confirmed locally recurrent or metastatic renal cell carcinoma with clear cell histology, a Karnof

202 ucture, vascular perfusion, and hypoxia of a renal cell carcinoma xenograft model grown in the chorio

203 nign skin tumours, lung and kidney cysts and renal cell carcinoma(6,7).

204 is associated with other malignancies (e.g. renal cell carcinoma), little is known about the role of

205 -treated cohorts (patients with melanoma and renal cell carcinoma).

206 (10%) of 31 (melanoma), and 14 (40%) of 35 (renal cell carcinoma).

207 In renal cell carcinoma, 8 samples reduced the list of clon

208 naive tumors, a papillary transitional cell renal cell carcinoma, a duodenal carcinoma, two metachro

209 s pheochromocytoma and paraganglioma (PPGL), renal cell carcinoma, and gastrointestinal stromal tumor

210 ed melanoma, reduced the need for surgery in renal cell carcinoma, and increased the number of patien

211 icates complement in the immune landscape of renal cell carcinoma, and notwithstanding cohort size an

212 2) is active against metastatic melanoma and renal cell carcinoma, but treatment-associated toxicity

213 olizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classical

214 circumstances and to cancer (paraganglioma, renal cell carcinoma, gastrointestinal stromal tumor) in

215 who undergo radical resection for localized renal cell carcinoma, is the preservation of kidney func

216 presence of BAP1-associated cancers such as renal cell carcinoma, mesothelioma and meningioma, but n

217 d tissues from patients and murine models of renal cell carcinoma, pancreatic ductal adenocarcinoma,

218 nitially effective against kidney cancer (or renal cell carcinoma, RCC); however, drug resistance fre

219 With the exception of renal cell carcinoma, studies assessing the association

220 ated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile.

221 included patients with metastatic clear cell renal cell carcinoma, with at least one target lesion at

222 itinib monotherapy in patients with advanced renal cell carcinoma.

223 axitinib as the standard of care of advanced renal cell carcinoma.

224 nib monotherapy in treatment-naive, advanced renal cell carcinoma.

225 een VHL and the m(6)A RNA demethylase FTO in renal cell carcinoma.

226 ab versus sunitinib in first-line metastatic renal cell carcinoma.

227 t option for selected patients with advanced renal cell carcinoma.

228 , breast and colorectal cancers, melanoma or renal cell carcinoma.

229 gastrointestinal stromal tumour (wtGIST) and renal cell carcinoma.

230 with TSC include angiomyolipoma, cysts, and renal cell carcinoma.

231 ing lymphocytes in the context of clear cell renal cell carcinoma.

232 s at intermediate or poor risk with advanced renal cell carcinoma.

233 rome, known as hereditary leiomyomatosis and renal cell carcinoma.

234 , and 22.7 months (20.9-27.0) for those with renal cell carcinoma.

235 tandard of care for patients with metastatic renal cell carcinoma.

236 nephrectomy (CN) in patients with metastatic renal cell carcinoma.

237 or poor risk, previously untreated, advanced renal cell carcinoma.

238 kers of survival in patients with metastatic renal cell carcinoma.

239 cy of treatments in patients with clear cell renal cell carcinoma.

240 nt of an aggressive form of type 2 papillary renal cell carcinoma.

241 ic target for the treatment of VHL-deficient renal cell carcinoma.

242 y associated diseases including leukemia and renal cell carcinoma.

243 y of cabozantinib in advanced non-clear-cell renal cell carcinoma.

244 on correlates with poor clinical outcomes in renal cell carcinoma.

245 t to delay disease progression in clear cell renal cell carcinoma.

246 plus nivolumab for the treatment of advanced renal cell carcinoma.

247 be (chRCC, also known as kidney chromophobe) renal cell carcinoma.

248 d with sorafenib in patients with metastatic renal cell carcinoma.

249 rth-line therapy in patients with metastatic renal cell carcinoma.

250 using data from a recent study for treating renal cell carcinoma.

251 ease progression in patients with metastatic renal cell carcinoma.

252 ic urothelial carcinoma (mUC) and metastatic renal cell carcinoma.

253 correlated with YAP activation in clear cell renal cell carcinoma.

254 genes was linked to unfavorable prognosis in renal cell carcinoma.

255 expressed in kidney, and is downregulated in renal cell carcinoma; also, its low expression correlate

256 cer, 37 (33%) had melanoma, and 38 (34%) had renal cell carcinoma; one (<1%) patient had triple-negat

257 tion have been well described for clear cell renal cell carcinomas (ccRCC), but they are less studied

258 genetic event in the majority of clear cell renal cell carcinomas (ccRCC), leading to accumulation o

259 Most clear cell renal cell carcinomas (ccRCCs) have inactivation of the

260 is a critical tumor suppressor in clear cell renal cell carcinomas (ccRCCs).

261 CR ligands were expressed by patient-derived renal cell carcinomas (PD-RCC), and selective inactivati

262 he histomorphological subtyping of papillary renal cell carcinomas (pRCCs) has improved the predictio

263 cluding normal kidney, renal oncocytoma, and renal cell carcinomas (RCC).

264 hereas EMT contributes to the development of renal cell carcinomas (RCC).

265 t can occur in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poo

266 for 100 consecutive biopsy-proved stage T1a renal cell carcinomas (RCCs) treated with percutaneous m

267 Sarcomatoid clear-cell renal cell carcinomas (sRCC) are associated with dismal

268 ansion of tumor-resident clones, we analyzed renal cell carcinomas from patients treated with stereot

269 For instance, ALK-rearranged renal cell carcinomas have shown responses to alectinib

270 ted MRI may be useful to identify clear cell renal cell carcinomas with higher growth rates.

271 g Wilms tumours, malignant rhabdoid tumours, renal cell carcinomas, and congenital mesoblastic nephro

272 ons in the tumor suppressor TP53 are rare in renal cell carcinomas.

273 safety of cabozantinib across non-clear-cell renal cell carcinomas.

274 t to all targeted agents used to treat other renal cell carcinomas.

275 erent from the approaches used for classical renal cell carcinomas.

276 ption factor family translocation-associated renal cell carcinomas.

277 (max) < 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and

278 llagen-induced DDR1 activation, we generated renal cells expressing wild-type or mutant forms of DDR1

279 However, infusions of normal adult rat renal cells have been a successful therapy in several ra

280 cule high-throughput screen (HTS) with human renal cells having an integrated luciferase construct hi

281 p27b1 is also expressed at low levels in non-renal cells, in which transcription was modulated exclus

282 tion is a potential early marker of ischemic renal cell injury and a therapeutic target.Methods Diffe

283 axitinib dosing in patients with metastatic renal cell inoma previously treated with checkpoint inhi

284 he intracellular sphingolipid composition of renal cells is an important determinant of renal functio

285 The renal cell line (HEK 293) was used to study lipotoxic in

286 responses and via crosstalk with surrounding renal cells, lymphatic vessels have been implicated in t

287 imary malignancies were lung (n = 125, 47%), renal cell (n = 38, 14%), melanoma (n = 33, 12%), sarcom

288 Intrarenal crystals trigger inflammation and renal cell necroptosis, processes that involve TNF recep

289 kidney-specific control module governed by a renal cell-specific chromatin structure located distal t

290 hreonine sites in NPM harvested from primary renal cells, tissue, and urine.

291 Chronic exposure of tubular renal cells to high glucose contributes to tubulointerst

292 trol mineral homeostasis and second in extra-renal cells to regulate target genes linked to specific

293 ges in the proportion and gene expression of renal cell types during injury and repair.

294 ne the function of CD73 expressed by various renal cell types under mild IRI conditions.

295 tity cells" (expressing markers of different renal cell types) that are normally seen only during ear

296 ine known genes, and maps gene expression to renal cell types.

297 ion patterns for multiple AKI stages and all renal cell types.

298 ated a significant increase in the number of renal cells undergoing mitosis (26%) compared with EMS p

299 atrix protein increase by activating AMPK in renal cells, we examined whether H2S inhibits high gluco

300 and PCDH9, and increased ICAM5 in muscle and renal cells, while ICAM5 knockdown reduced HIST1H3E expr